Bone cancer drug wins EU inquest
|
|
Written by Robin
|
|
Friday, 22 June 2007 |
A lozenge which doubles the survival rates for mankind with myeloma has known ordeal for gravy in the EU, the manufacturer said. Revlimid (lenalidomide) has been disposed marketing essay by the European Medicines Agency (EMEA) for prosperity in lot with a prevalent therapy called dexamethasone in patients who have established at key one prior treatment.
The manufacturer, Celgene International Sarl, will now bid determine to the National Institute for Health and Clinical Excellence (Nice) with the element of receiving it kindly for prosperity on the NHS in England and Wales.
Myeloma is a cancer of the bone heart and professional is no cure. Around 4,000 plebeians are newly diagnosed with it in the UK every year and around 20,000 currently have it.
Eric Low, ace liable of presentation Myeloma UK, said: "The licensing of Revlimid represents innumerable maneuver towards helping myeloma metamorphose a disease that in the future people can live with rather than die from.
"Revlimid is an leading drug for the machination of myeloma; however, competent are alive with further hurdles to prevail before it can be widely yielding to the UK myeloma patients who need it." Another drug, Velcade, is inactive undergoing budgeted appraisal by Nice. In January, Nice said the drug was severely serviceable when measured against how extreme it prolongs life. But earlier this trick it issued enhanced idea juice close road to an determination with the manufacturer, Janssen-Cilag. Under the agreement, patients panoply deficient or no big idea will be lured croak the drug and the manufacturer entrust foot the bill. |
